We have packaged ATRA in slow-releasing microparticles, which alone shows more potent inhibitory activity both on Pin1 degradation in vitro and HCC tumor growth in vivo (data unpublished), indicating that developing novel slow-releasing method applicable to patients is worth further exploring. This evidence concerns the gene PIN1 and neoplasm.